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CHAPTER 1. General introduction 
 
Cancer is a major world health problem, and it is predicted that there will be 
approximately 26 million new cancer cases and 17 million cancer-related deaths 
annually by 2030 (1). The management of cancer currently suffers from several issues. 
Cancer treatment strategies include radiation therapy, chemotherapy, and a combination 
of these, chemoradiotherapy, all of which exert cytotoxicity on cancer cells (2,3). In 
addition, specific inhibitors are available, which are used for cancer therapy, such as 
receptor tyrosine kinase or kinase inhibitors, in the form of monoclonal antibodies or 
small organic molecules (4,5,6). Although these treatments lead to improvements in 
many tumor types, they can cause severe side effects and delayed neurotoxicity owing 
to their non-specific mechanisms, which is the first crucial matter. The second issue is 
the development of resistance, which is caused by various factors. Many conventional 
anticancer reagents target factors related to cancer cell growth and show poor tumor 
penetration, resulting in reduced sensitivity of hypoxic cells in tumors that are in a 
growth-arrested state (7). Therefore, to combat cancer, it is necessary to develop an 
innovative and unique therapeutic strategy.  
Antimicrobial peptides (AMPs) are host defense molecules of the innate 
immune system of all life forms (8,9).  In the AMP database, there are over 2,700 such 
peptides (10). AMPs typically contain fewer than 100 amino acids and occur in many 
cell types. They are generally cationic and amphipathic, and homologous peptides exist 
in vertebrates, invertebrates, and plants. Recently, they have been characterized as 
multifunctional peptides that serve a variety of biological roles, such as immune 
regulation, wound healing, angiogenesis, and anticancer functions (Figure 1).  Human 
cationic antibacterial protein of 18 kDa (hCAP18, also called LL-37 or FALL39) is the 
only cathelicidin AMPs in humans, and has an α-helical structure that forms 
amphipathicity (Figure 2). The interactions between AMPs and cancer cells influence 
apoptotic or other pathways and can result in cell death. Based on their multifunctional 
activities, there is a growing interest in the development of AMPs as anticancer agents. 
 In this thesis, I confirmed the efficacy of AMPs on colon cancer cells and 
attempted to reveal its mechanisms, especially focusing on the interaction of 
metabolism and microRNAs. 
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CHAPTER 2. Anti-proliferative effect of an analogue of the LL-37 peptide in the 
colon cancer derived cell line HCT116 p53+/+ and p53-/- 
 
 As described in chapter 1, antimicrobial peptides of the cathelicidin family are 
found in many mammalian species, and are focused on various effects other than 
antimicrobial action. In this chapter, we evaluated the anti-proliferative effect of 
cathelicidin antimicrobial peptide, LL-37 and its analogue peptide, FF/CAP18 against 
the colon cancer cell line HCT116. Cell count and WST-8 assay showed that FF/CAP18 
significantly decreased the proliferation of HCT116 cells in a dose-dependent fashion, 
and its effect are stronger than LL-37 (Figure 3). AnnexinV and 7-Amino-Actinomycin 
D staining revealed that HCT116 cells were induced apoptotic cell death by treatment 
with FF/CAP18 (Figure 4).  Furthermore, the treatment of HCT116 with FF/CAP18 
caused loss of mitochondrial membrane potential (Figure 5), suggesting the early stage 
of apoptosis, and resulted in the immune-reactivity to the single-strand DNA antibody 
(Figure 6). To confirm the effect of FF/CAP18 in vivo, we administrated FF/CAP18 to 
xenograft nude mice inoculated HCT116 cells.  Tumor volume in mice administrated 
FF/CAP18 was significantly lower than control group (Figure 7). Interestingly, the 
anti-proliferative effect of FF/CAP18 was constant regardless of the genotype of p53 
(wild-type and p53 mutant type HCT116 cells) (Figure 8). Therefore, the signaling 
pathway of p53 is not involved in the growth suppression effect of the cathelicidin 
analogue peptide. Although further experiments to reveal the detailed mechanisms are 
required, these results indicate that antimicrobial peptides such as LL-37 and FF/CAP18 
have the possibility for novel therapeutic agents. 
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CHAPTER 3. Antimicrobial peptide FF/CAP18 induces apoptotic cell death in 
HCT116 colon cancer cells via changes in the metabolic profile 
 
 Metabolic reprogramming is one of the hallmarks of cancer and can be 
targeted by therapeutic agents. We described in chapter 2 that cathelicidin-related or 
modified antimicrobial peptides, such as FF/CAP18, have antiproliferative effects on 
the colon carcinoma cell line HCT116 through apoptotic cell death. Although 
antimicrobial peptides have potential use in the development of new therapeutic 
strategies, their effects on the metabolism of cancer cells are poorly understood. In this 
chapter, we investigated changes in the levels of metabolites in HCT116 cells caused by 
FF/CAP18, via capillary electrophoresis time-of-flight mass spectrometry (CE-TOFMS). 
Analysis of the 177 intracellular metabolites and 113 metabolites in conditioned 
medium that were detected by CE-TOFMS, revealed dramatic changes in the metabolic 
profile of HCT116 cells after treatment with FF/CAP18. The metabolomic profile of 
HCT116 cells treated with 10 µg/ml FF/CAP18 showed high values for the metabolites 
in cluster 2, including amino acids, and tricarboxylic acid (TCA) cycle intermediates. In 
contrast, the metabolomic profile of HCT116 cells treated with 40 µg/ml FF/CAP18 
was reversed in comparison to the profile for treatment with 10 µg/ml FF/CAP18 
(Figure 9). This trend was made even clearer from the results of the Principal 
component analysis (PCA) of metabolome data for HCT116 cells treated with 
FF/CAP18 (Figure 10). The metabolic profile showed that the levels of most 
metabolites in the major metabolic pathways supported the rapid proliferation of cancer 
cells. Purine metabolism (Figure 11), glycolysis (Figure 12), and the TCA cycle (Figure 
13), were altered in FF/CAP18-treated cells in a dose-dependent manner. These 
observations provide mechanistic insights into the anticancer effects of antimicrobial 
peptides that show great potential as new therapies for colon cancer. 
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CHAPTER 4. miR-663a regulates growth of colon cancer cells, after 
administration of antimicrobial peptides, by targeting CXCR4-p21 pathway 
 
 MicroRNAs (miRNAs) are small, endogenous, single-stranded RNAs of 18–
22 nucleotides in length, that are emerging as important modulators of gene expression. 
miRNAs participate in diverse biological processes such as cell differentiation, 
proliferation, and apoptosis through a myriad of targets. Recent studies have provided 
several insights into the relationship between miRNAs and colon cancer, and miRNAs 
are potential crucial for successful colon cancer therapy. In this chapter, we report the 
regulation and effects of miRNAs expression by AMPs in colon cancer cells. miRNA 
array analysis revealed that 17 miRNAs were increased 2-fold or greater in HCT116 
cells after treatment with LL-37 (40 µg/mL) compared to that in non-treated cells 
(Table 2).  miR-663a is a major upregulated miRNA by administration of the human 
cathelicidin AMP, LL-37, and its analogue peptide, FF/CAP18, in the colon cancer cell 
line HCT116 (Figure 14). Over-expression of miR-663a caused anti-proliferative effects 
both in vitro (Figure 15) and in vivo (Figure 16). We also provide evidence supporting 
the view that these effects are attributed to suppression of the expression of the 
chemokine receptor CXCR4, resulting in the abrogation of phosphorylation of Akt and 
cell cycle arrest in G2/M via p21 activation (Figure 17).  
These studies contribute to the understanding of the AMPs’ mediated anti-cancer 
mechanisms in colon cancer cells and highlights the possibility of using AMPs and 
miRNAs towards developing future strategies for cancer therapy. 
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CHAPTER 5. Conclusion 
 
We revealed that human cathelicidin antimicrobial peptide, LL-37, and its 
analogue, FF/CAP18 suppress the proliferation of colon cancer cells via apoptotic cell 
death, changes in the levels of metabolites and the upregulation of miR-663a abrogating 
CXCR4 expression. We describe main results and findings below; 
 
1. Human cathelicidin antimicrobial peptide, LL-37 and its analogue peptide, 
FF/CAP18 have anti-proliferative effect on human colon cancer cell line, HCT116 
cells. Furthermore, FF/CAP18 induced depolarization of the partial mitochondrial 
membrane and fragmentation of DNA, which are events of apoptosis in the earlier 
and final stage, respectively. The further key finding in this study is that the 
antiproliferative effect of this peptide is independent from the p53 signaling 
pathway. 
 
2. PCA and HCA of large-scale metabolic profiling demonstrated remarkable 
differences between non-treated HCT116 cells, cells treated with FF/CAP18 at 10 
μg/ml, and cells treated with 40 μg/ml FF/CAP18. A great number of metabolites, 
including nucleotides, TCA cycle components, and amino acids in HCT116 cells, 
increased in HCT116 cells after treatment with FF/CAP18 at 10 μg/ml compared 
with non-treated cells, indicating that FF/CAP18 could induce favorable metabolic 
conditions at this comparatively low concentration. On the other hand, at a 
concentration of 40 μg/ml, FF/CAP18 caused shortages of various metabolites. 
 
3. We identified miR-663a as the upregulated miRNA in the colon cancer cell line 
HCT116 treated with human cathelicidin AMP, LL-37 and its analogue, FF/CAP18. 
Moreover, we revealed that upregulated miR-663a in HCT116 cells induced the 
suppression of growth through cell cycle arrest at the G2/M phase. Furthermore, we 
confirmed down-regulation of C-X-C chemokine receptor type 4 (CXCR4) and 
upregulation of p21 in HCT116 cells treated with FF/CAP18, which demonstrates 
that one of the pathways of the anti-cancer mechanism of AMPs can be triggered by 
targeting CXCR4 and activating the downstream signals. 
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These data support AMPs can act against cancer, including colon cancer, through a 
variety of mechanisms of action, and the modulation of metabolites and miRNAs could 
not be all factors inducing the negative affect on cancer by the administration of AMPs. 
However, we believe these studies contributes to the understanding of anti-cancer 
mechanisms in colon cancer cells treated with AMPs, and highlights the possibility of 
using AMPs for future strategies in cancer therapy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
248
Table 1. Upregulated miRNAs in HCT116 treated with AMPs 
 Fold Change 
 LL-37  FF/CAP18 
miRNA 40 µg/mL 80 µg/mL  40 µg/mL 
hsa-miR-3663-3p 162.04 ND  58.19 
hsa-miR-4271 145.10 ND  359.22 
hsa-miR-630 139.54 ND  194.83 
hsa-miR-371a-5p 123.04 ND  ND 
hsa-miR-1181 112.97 ND  ND 
hsa-miR-575 112.85 ND  315.56 
hsa-miR-939-5p 96.13 ND  83.80 
hsv2-miR-H6-5p 94.15 ND  ND 
hsa-miR-663a 61.85 215.81  277.49 
hsa-miR-135a-3p 27.81 ND  ND 
hsa-miR-132-3p 3.21 ND  ND 
kshv-miR-K12-3-5p 3.16 3.09  ND 
hsa-miR-10a-5p 3.05 ND  ND 
hsa-miR-762 3.03 2.16  ND 
hsa-miR-513a-5p 2.26 4.59  8.37 
hsa-miR-99a-5p 2.10 ND  ND 
hsa-miR-1915-3p 2.09 2.41  ND 
(ND: Not detectable) 
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Figure 1. Various effects of Antimicrobial peptides (AMPs).	
AMPs have various effects such as immune regulation, wound healing, angiogenesis and 
anticancer effects other than antimicrobial effects.	
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Figure 2. hCAP18 and LL-37 in cathelicidin family. (A) The human cathelicidin hCAP18 
consists of signal peptide (30 amino acids), N-terminal domain (103 amino acids), and C-
terminal domain (37 amino acids).  C-terminal domain shows various activities as active 
domain, and is called LL-37. (B) LL-37 has an α-helical structure, that forms an 
amphipathic property.	
A B
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 Figure 3. LL-37 and FF/CAP18 show anti-proliferative effects on HCT116. (A) Cells 
were treated with LL-37 or FF/CAP18 at 40 μg/ml for 96 h at 37˚C. Each time point 
contains 4-5 duplications, and the mean value and SE are shown. The asterisks indicate	
the statistical significance. **P<0.01. (B) Viability of HCT116 cells after treatment with 
LL-37, FF/CAP18, or Sc/FF for 48 hours at the concentration of 100–1.5625 µg/mL. 
Each data is presented as mean ± SD of triplicate experiments. (* p < 0.05; ** p < 0.001).	
A B
Figure 4. LL-37 and FF/CAP18 show anti-proliferative effects on HCT116. (A) Cells 
were treated with LL-37 or FF/CAP18 at 40 μg/ml for 96 h at 37˚C. Each time point 
contains 4-5 duplications, and the mean value and SE are shown. The asterisks indicate	
the statistical significance. **P<0.01. (B) Viability of HCT116 cells after treatment with 
LL-37, FF/CAP18, or Sc/FF for 48 hours at the concentration of 100–1.5625 µg/mL. 
Each data is presented as mean ± SD of triplicate experiments. (* p < 0.05; ** p < 0.001).	
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100 µm
Figure 5. The detection of the disruption of mitochondria membrane with the 
mitocapture method. (A) The detection of the red fluorescence deposit on the 
mitochondria in wild-type HCT116 cells. (B) The results of FF/CAP18 treated 
HCT116.  Note  that  remarkable  reduction  of  the  red  fluorescence  was 
observed. Bar, 100 μm.	
50 µm
Figure 6. The detection of the genomic DNA fragmentation with single strand DNA 
antibody. (A-C) No treatment control. Results with anti ss-DNA antibody (A), DAPI 
staining (B), merge (C) are shown. (D-F) Positive control cells, treated with the DNAse 
I.  (G-I)  FF/CAP18  treated  cells.  Note  arrows  showing  positivity  for  anti  ss-DNA 
antibody. Bar, 50 μm.	
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 Figure 7. FF/CAP18 suppresses tumorigenesis of HCT116 in a xenograft model. (A) 
Growth curves of HCT116 tumors after simultaneous injection of nude mice with FF/
CAP18 (square) or control peptide, Sc/FF (triangle).  The volume of the tumors was 
derived from both cells  evaluated at  2-day intervals  for  14 days and plotted as  the 
percentage relative to day 0. Each plot is shown as mean ± SD of four experiments (* p 
< 0.05; ** p < 0.001). (B) Tumor weight was measured 14 days after inoculation of 
HCT116 cells with Sc/FF and FF/CAP18. Each plot is shown as mean ± SD of four 
experiments (* p < 0.05). (C) Photographs illustrating mice tumors derived from control 
cells treated with Sc/FF (Sc/FF: arrows) and HCT116 cells treated with FF/CAP18 (FF/
CAP18) 14 days after inoculation.	
Figure 8. The anti-proliferative effect of FF/CAP18 peptide to p53-/- HCT116 cells. 
HCT116 p53-/- cells were treated with or without FF/CAP18 (10 and 40 μg/ml) in cell 
culture medium for 96 h at 37˚C. Each time point contains five duplication, and its 
mean value and SE were plotted on the graph.  The asterisks  indicate  the statistical 
significance,  **P<0.01,  *P<0.05.  Note  that  p53-/-  HCT116  showed  the  identical 
phenotype with the wild-type HCT116.	
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 Figure  9.  Euclidean-distance-based  heat  map of  metabolites  in  non-treated  HCT116 
cells (left), and HCT116 cells treated with FF/CAP18 at 10 μg/ml (middle) or 40 μg/ml 
(right). The color scale from green to red indicates low to high correlation, respectively. 
Hierarchical cluster analysis was carried out using the proprietary software, PeakStat.	
Figure 10. Principal component analysis (PCA) plot of metabolome analysis data that 
characterizes the trends exhibited by the expression profiles of  non-treated HCT116 
cells (blue), HCT116 cells treated with FF/CAP18 at 10 μg/ml (red) and HCT116 cells 
treated with FF/CAP18 at 40 μg/ml (green). The x-axis shows the distance of PC1 and 
the y-axis shows the distance of PC2 in the scatter plot. PCA was carried out using the 
proprietary software, SampleStat.	
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 Figure 11. Metabolome data map of the purine metabolic pathway in HCT116 cells 
(cell-derived data) and conditioned medium (medium-derived data). Each bar represents 
the relative amount of a metabolite for non-treatment (black), treatment with FF/CAP18 
at  10  μg/ml  (deep  grey)  or  40  μg/ml  (light  grey)  and  control  medium (white).  All 
metabolite data are shown as the mean of triplicate samples ± standard deviation. The P-
values  were  evaluated  using  Student's  t-test.  The  asterisks  indicate  the  statistical 
significance. *P<0.05; **P<0.01; ***P<0.001.	
Figure  12.  Metabolome data  map of  the  glycolysis  metabolic  pathway and PPP,  in 
HCT116  cells  and  in  conditioned  medium (medium data).  Each  bar  represents  the 
relative amount of a metabolite for non-treatment (black), treatment with FF/CAP18 at 
10  μg/ml  (deep  grey)  or  40  μg/ml  (light  grey)  and  control  medium  (white).  All 
metabolite data are shown as the mean of triplicate samples ± standard deviation. The P-
values  were  evaluated  using  Student's  t-test.  The  asterisks  indicate  the  statistical 
significance. *P<0.05; **P<0.01; ***P<0.001.	
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 Figure  13.  Metabolome  data  map  of  the  TCA cycle  in  HCT116  cells.  Each  bar 
represents the relative amount of a metabolite for non-treatment (black), treatment with 
FF/CAP18  at  10  μg/ml  (deep  grey)  or  40  μg/ml  (light  grey),  and  control  medium 
(white).  All  metabolite data are shown as the mean of triplicate samples ± standard 
deviation. The P-values were evaluated using Student's t-test. The asterisks indicate the 
statistical significance. *P<0.05; **P<0.01; ***P<0.001.	
Figure  14.  The  RT-qPCR  analysis  showed  that  HCT116  cells  transduced  with 
miR-663a-expressing vector expressed miR-663a. Each data is shown as mean ± SD 
of triplicate experiments. (* p < 0.05, ** p < 0.001).	
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Figure  15.  Proliferation  of  HCT116  cells  (wt)  and  HCT116  cells  transduced  with 
lentiviruses  harboring  control  vector  (miR-ctrl)  and  miR-663a-expressing  vector 
(miR-443  663a)  for  4  days.  Each  data  is  presented  as  mean  ±  SD  of  triplicate 
experiments. (** p < 0.001).	
Figure  16.  miR-663a  suppresses  tumorigenesis  of  HCT116  in  a  xenograft  model. 
Growth  curves  of  HCT116  tumors  after  nude  mice  were  injected  with  miR-663a 
(square) or control miRNA (triangle). The volume of the tumors derived from both cells 
was evaluated at 2-day intervals for 14 days and plotted as the percentage relative to 
day 0. Each plot is shown as mean ± SD of four experiments (* p < 0.05; ** p < 0.001).	
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Figure 17. Putative model of anti-cancer effect of AMPs in HCT116 cells. miR-663a 
upregulated  by  AMPs  suppresses  CXCR4  expression  leading  to  reduced 
phosphorylation of Akt. Consequently, p21 and the inactive form of cdc2 accumulation 
are caused, which results in the cell cycle arrest at the G2/M phase.	
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題 目 
Molecular mechanisms of anticancer effect on colon cancer 
cells by human cathelicidin antimicrobial peptide and its 
analogue（ヒトカテリシジン抗菌ペプチドおよびアナログ体
による大腸癌細胞に対する抗癌作用の分子機構） 
論 文 審 査 の 結 果 の 要 旨 
我が国において、癌は 1981 年から死亡原因の一位となり、人々の健康を 
脅かす大きな問題となっている。本研究では癌治療への新たなアプローチ 
として自然免疫系の重要な因子である抗菌ペプチド（Antimicrobial 
peptide: AMP）に注目した。ヒトカテリシジンファミリーの AMP としては 
hCAP18/LL-37 が唯一知られ、活性ドメインの C 末端（37 残基）は、27 
残基でも抗菌活性を維持することやヒトの口腔扁平上皮癌細胞に対してア 
ポトーシス様の細胞死を引き起こすことが報告されている。しかし、大腸 
癌をはじめ他の種類の癌細胞への作用や細胞死の詳細なメカニズムにつ 
いては不明であった。そこで、AMP の持つ癌細胞への作用の詳細を明らか 
にし、現存する癌化学療法における最大の問題である副作用を軽減した治 
療法を構築する基礎的なデータを獲得することを目的とした。 
hCAP18/LL-37 の活性部位の両端から 5 残基を取り除き、組成アミノ酸の 
 
 
一部を別のアミノ酸に置換したペプチドは大腸癌由来 HCT116 に強い増殖 
抑制作用を示した。その作用メカニズムに関して、アポトーシスの際に生 
じるミトコンドリア膜の脱分極や DNA の断片化が起きていることが分か 
った。この作用に p53 遺伝子が関与するかどうかを検討したところ、 
遺伝子欠損株でも同様の増殖抑制が見られた。そのメカニズム解明のため 
抗菌ペプチド処理後に発現量が増減する miRNA に着目し、網羅的 
にアレイ解析を行った。hCAP18/LL-37 およびアナログ体において 
濃度依存的に発現が上昇する miR-663a を見出した。さらに、miR-663a 
強制発現大腸癌細胞を樹立し、miR-663a がどのような影響を与えるか 
を調べた。強制発現大腸癌細胞では細胞が老化様形態を示し、増殖が抑 
制された。細胞周期を調べると G2/M 期で停止している細胞が多く存在 
していた。AMP は miR-663a の発現誘導後 CXCR4 を抑制し、p53 非依 
存的に細胞周期調節に重要な p21 を介した制御を行っていると考えら 
れた。大腸癌細胞を移植し抗菌ペプチドを投与した群および miR-663a 
を強制発現させた大腸癌細胞を移植したマウスでは、コントロール群に 
比べ、腫瘍形成が抑えられた。CE-TOFMS によるメタボローム解析によ 
って、AMP で処理した HCT116 では解糖系における代謝内で律速段階をつ 
くり、PPP へ代謝を迂回させていることが分かった。 
 本研究は AMP による抗癌作用の分子機構に関する基盤研究として重要な知 
見を提示している。審査員一同は本論文提出者に対して博士（農学）の学位を 
授与するのに値するものと判定した。 
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